体内CAR-Tin vivo CAR-T

体内重编程T细胞

每条都摘自下方编号的来源原文;只写事实,不写预测或建议。

未定事项

  • 辉瑞取得许可的三项自身免疫疾病体内CAR-T项目均处于IND申报前阶段。1
    Under the agreement, Pfizer obtains exclusive rights outside Greater China to develop, manufacture and commercialize three pre-IND in vivo chimeric antigen receptor T-cell (CAR-T) programs that are focused on treating autoimmune diseases.

相关卡片

来源

  1. Pfizer · Pfizer Enters into Exclusive Licensing Agreement with Starna Therapeutics for Autoimmune Diseases | Pfizer · 2026-11-18